Federal IDR outcomes: Intraoperative neuromonitoring in Arkansas
In 2025 Q1–Q4, the provider or facility offer prevailed in 86.7% of 2,294 determined Federal IDR dispute line items for intraoperative neuromonitoring in Arkansas. The median prevailing offer was 23.36x the QPA (25th–75th percentile 9.36x–49.28x; n = 1,190). The median time to a decision was 33 business days (n = 2,294).
Determined line items
2,294
2025 Q1–Q4 · 0 split decisions excluded
Provider win rate
86.7%
n = 2,294 · 2025 Q1–Q4
Median days to decision
33
business days, from dispute initiation · n = 2,294 · 2025 Q1–Q4
Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.
By period
| Period | Line items | Win % | Median ×QPA | 25th–75th | Ratio n | Median days |
|---|---|---|---|---|---|---|
| 2025 Q1–Q4 | 2,294 | 86.7% | 23.36x † | 9.36x–49.28x | 1,190 | 33 |
| 2024 Q1–Q4 | 1,714 | 92.8% | 15.27x | 4.97x–29.52x | 549 | 41 |
| 2023 Q1–Q4 | Fewer than 30 determined line items; not shown. | |||||
| 2023 Q1–2025 Q4 | 4,013 | 89.3% | 20.21x † | 7.66x–41.88x | 1,743 | not pooled |
Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.
Most disputed CPT codes
| CPT code | Line items | Win % | Median ×QPA | Ratio n | Median days |
|---|---|---|---|---|---|
| 95938 Placement of skin electrodes and measurement of stimulated sites on arms and leg | 534 | 87.3% | 57.03x † | 292 | 32 |
| 95861 Needle measurement of electrical activity in arm or leg muscles, 2 extremities | 317 | 90.2% | 19.40x | 174 | 30 |
| 95927 Placement of skin electrodes and measurement of stimulated sites in trunk or hea | 218 | 85.8% | 56.92x † | 91 | 35.5 |
| 95941 Continuous remote monitoring of nervous system during operation, each hour | 207 | 91.3% | 9.43x | 115 | 30 |
| 95939 Placement of skin electrodes and measurement of central motor stimulation in arm | 179 | 89.4% | 28.58x † | 83 | 33 |
| 95868 Needle measurement of electrical activity in muscles on both sides of body | 91 | 81.3% | 23.39x † | 43 | 38 |
| 95937 Testing of nerve-muscle junction | 69 | 84.1% | – | 17 | 105 |
| 95822 Measurement of brain wave activity (EEG), in coma or asleep | 66 | 89.4% | 27.87x † | 40 | 28.5 |
| 95955 Measurement of brain wave activity (EEG) outside the brain during surgery | 60 | 90.0% | 20.82x † | 52 | 30.5 |
| 95865 Needle measurement of electrical activity in voice box muscles | 36 | 77.8% | – | 17 | 29 |
2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.
Related: all specialties in Arkansas · Intraoperative neuromonitoring in all states
FAQ
What is the Federal IDR provider win rate for intraoperative neuromonitoring in Arkansas?
In 2025 Q1–Q4, the provider or facility offer was selected in 86.7% of 2,294 determined dispute line items for intraoperative neuromonitoring in Arkansas. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.
How do Federal IDR payments compare with the QPA for intraoperative neuromonitoring in Arkansas?
In 2025 Q1–Q4, the median prevailing offer was 23.36x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 9.36x to 49.28x (n = 1,190 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.
How long do Federal IDR decisions take for intraoperative neuromonitoring in Arkansas?
In 2025 Q1–Q4, the median was 33 business days (n = 2,294 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).